Although this perspective may include some subjective assessment, it suggests that the primary candidates for such monitoring might be limited to cases where complete resection is deemed challenging, such as tumors involving multiple lobes with unresectable enhancing components, or recurrent IDH-mutant gliomas. Here, IDH1 is linked to glioma.